New York, June 11, 2026, 17:02 ET
- Moderna finished at $49.64, gaining 7.94%. The stock touched $49.94 at its high for the session.
- The move followed big gains for the Nasdaq, S&P 500 and Dow, which all closed up.
- Investors are watching Moderna’s mRNA cancer-vaccine pipeline. UK regulators recently cleared a new trial.
Moderna Inc. (NASDAQ: MRNA) bounced back on Thursday, finishing the session at $49.64 for a gain of $3.65, or 7.94%. Shares started the day at $46.43 and moved between $46.30 and $49.94. Wednesday saw the stock drop 3.65% to close at $45.99, Investing.com data showed. The stock slipped to $49.16 in early after-hours trade near 5 p.m. ET.
The rally matched a broader move up in U.S. stocks, with no confirmed news out of the company during Thursday’s session. Reuters said the S&P 500 jumped 1.75%, the Nasdaq climbed 2.53% and the Dow was up 1.84% as stocks pushed higher after President Donald Trump said planned strikes on Iran were called off. “Our technical indicators are looking relatively oversold here,” Robert Phipps, director at Per Stirling Capital Management, told Reuters. Reuters
Moderna stayed in the spotlight, with traders watching the biotech name closely as usual around vaccine, cancer, and cash-burn news. Shares beat the Nasdaq on Thursday. But moves in the wider index helped set the mood, boosting growth and healthcare stocks as risk appetite picked up.
Moderna’s pipeline is still in focus after news from Oxford Cancer on June 9. The company said Phase 1 of the INTERCEPT-Lynch trial, which is backed by Moderna and run by the University of Oxford, got the green light from the UK Medicines and Healthcare products Regulatory Agency and aims to start signing up patients this summer. The trial is looking at Moderna’s experimental mRNA-based cancer vaccine mRNA-4194 in people with Lynch syndrome. That’s a genetic condition that affects about one in 300 globally and carries a lifetime cancer risk as high as 80%.
Moderna chief development officer David Berman called the MHRA authorization “an important milestone.” Professor David Church at the University of Oxford said the INTERCEPT-Lynch trial is a “meaningful step” for preventing cancers linked to Lynch syndrome before they start. Oxford Cancer said mRNA-4194 aims to train the immune system to spot and clear pre-cancerous cells. Oxford Cancer Centre
The oncology pipeline goes beyond the Lynch syndrome work. Reuters said this week that over 130 studies at the American Society of Clinical Oncology meeting looked at mRNA cancer vaccines. Moderna and Merck’s experimental personalized mRNA cancer shot, combined with immunotherapy, was featured for five-year melanoma results. According to Reuters, the companies are also running nine big and midsize cancer trials testing mRNA therapies across lung, kidney, bladder and pancreatic cancers.
Moderna’s latest bounce hasn’t moved the needle much for Wall Street analysts. StockAnalysis says the average view from 23 analysts is still “Hold,” putting a 12-month target price at $43.30, lower than what the stock closed at on Thursday. TipRanks/The Fly wrote this week that BofA bumped its Moderna target up to $34 from $32 but stayed at Underperform. BofA cited better expectations for norovirus ahead of a Phase 3 trial result set for later this year. StockAnalysis
Moderna’s financials are still central to its pitch. The biotech reported first-quarter revenue climbed to $389 million from $108 million a year ago, according to its May 1 release. At the same time, its GAAP net loss widened to $1.3 billion, weighed by a $0.9 billion charge tied to a one-time litigation settlement. Moderna finished March with $7.5 billion in cash, cash equivalents and investments, and repeated its outlook for up to 10% growth in revenue for 2026.
